These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 31311404)
1. MDM2 inhibitor RG7388 potently inhibits tumors by activating p53 pathway in nasopharyngeal carcinoma. Fan X; Wang Y; Song J; Wu H; Yang M; Lu L; Weng X; Liu L; Nie G Cancer Biol Ther; 2019; 20(10):1328-1336. PubMed ID: 31311404 [TBL] [Abstract][Full Text] [Related]
2. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models. Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271 [TBL] [Abstract][Full Text] [Related]
3. Co-delivery of p53 and MDM2 inhibitor RG7388 using a hydroxyl terminal PAMAM dendrimer derivative for synergistic cancer therapy. Chen K; Xin X; Qiu L; Li W; Guan G; Li G; Qiao M; Zhao X; Hu H; Chen D Acta Biomater; 2019 Dec; 100():118-131. PubMed ID: 31568878 [TBL] [Abstract][Full Text] [Related]
4. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593 [TBL] [Abstract][Full Text] [Related]
5. TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist. Xu C; Liu H; Pirozzi CJ; Chen LH; Greer PK; Diplas BH; Zhang L; Waitkus MS; He Y; Yan H Acta Neuropathol Commun; 2021 Nov; 9(1):178. PubMed ID: 34732238 [TBL] [Abstract][Full Text] [Related]
6. Discovery of Novel p53-MDM2 Inhibitor (RG7388)-Conjugated Platinum Liu W; Ma Y; He Y; Liu Y; Guo Z; He J; Han X; Hu Y; Li M; Jiang R; Wang S J Med Chem; 2024 Jun; 67(11):9645-9661. PubMed ID: 38776419 [TBL] [Abstract][Full Text] [Related]
7. The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents. Canon J; Osgood T; Olson SH; Saiki AY; Robertson R; Yu D; Eksterowicz J; Ye Q; Jin L; Chen A; Zhou J; Cordover D; Kaufman S; Kendall R; Oliner JD; Coxon A; Radinsky R Mol Cancer Ther; 2015 Mar; 14(3):649-58. PubMed ID: 25567130 [TBL] [Abstract][Full Text] [Related]
8. Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment. Yee-Lin V; Pooi-Fong W; Soo-Beng AK Mini Rev Med Chem; 2018; 18(2):173-183. PubMed ID: 28714398 [TBL] [Abstract][Full Text] [Related]
9. Anticancer targets and mechanisms of calycosin to treat nasopharyngeal carcinoma. Liu F; Pan Q; Wang L; Yi S; Liu P; Huang W Biofactors; 2020 Jul; 46(4):675-684. PubMed ID: 32449282 [TBL] [Abstract][Full Text] [Related]
10. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner. Feng FY; Zhang Y; Kothari V; Evans JR; Jackson WC; Chen W; Johnson SB; Luczak C; Wang S; Hamstra DA Neoplasia; 2016 Apr; 18(4):213-22. PubMed ID: 27108384 [TBL] [Abstract][Full Text] [Related]
12. Cell Cycle Arrest and Cytotoxic Effects of SAHA and RG7388 Mediated through p21 Natarajan U; Venkatesan T; Radhakrishnan V; Samuel S; Rasappan P; Rathinavelu A Medicina (Kaunas); 2019 Jan; 55(2):. PubMed ID: 30700046 [TBL] [Abstract][Full Text] [Related]
13. Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer. Zanjirband M; Edmondson RJ; Lunec J Oncotarget; 2016 Jun; 7(26):40115-40134. PubMed ID: 27223080 [TBL] [Abstract][Full Text] [Related]
14. Ablation of Cancer Stem Cells by Therapeutic Inhibition of the MDM2-p53 Interaction in Mucoepidermoid Carcinoma. Andrews A; Warner K; Rodriguez-Ramirez C; Pearson AT; Nör F; Zhang Z; Kerk S; Kulkarni A; Helman JI; Brenner JC; Wicha MS; Wang S; Nör JE Clin Cancer Res; 2019 Mar; 25(5):1588-1600. PubMed ID: 30498096 [TBL] [Abstract][Full Text] [Related]
15. Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma. Chen L; Rousseau RF; Middleton SA; Nichols GL; Newell DR; Lunec J; Tweddle DA Oncotarget; 2015 Apr; 6(12):10207-21. PubMed ID: 25844600 [TBL] [Abstract][Full Text] [Related]
16. Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib. Berberich A; Kessler T; Thomé CM; Pusch S; Hielscher T; Sahm F; Oezen I; Schmitt LM; Ciprut S; Hucke N; Ruebmann P; Fischer M; Lemke D; Breckwoldt MO; von Deimling A; Bendszus M; Platten M; Wick W Clin Cancer Res; 2019 Jan; 25(1):253-265. PubMed ID: 30274984 [TBL] [Abstract][Full Text] [Related]
17. SALL4 induces radioresistance in nasopharyngeal carcinoma via the ATM/Chk2/p53 pathway. Nie X; Guo E; Wu C; Liu D; Sun W; Zhang L; Long G; Mei Q; Wu K; Xiong H; Hu G Cancer Med; 2019 Apr; 8(4):1779-1792. PubMed ID: 30907073 [TBL] [Abstract][Full Text] [Related]
18. An oral 2-hydroxypropyl-β-cyclodextrin-loaded spirooxindole-pyrrolizidine derivative restores p53 activity via targeting MDM2 and JNK1/2 in hepatocellular carcinoma. Gao X; Wei M; Shan W; Liu Q; Gao J; Liu Y; Zhu S; Yao H Pharmacol Res; 2019 Oct; 148():104400. PubMed ID: 31425749 [TBL] [Abstract][Full Text] [Related]
19. Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner. Esfandiari A; Hawthorne TA; Nakjang S; Lunec J Mol Cancer Ther; 2016 Mar; 15(3):379-91. PubMed ID: 26832796 [TBL] [Abstract][Full Text] [Related]
20. Nutlin-3 sensitizes nasopharyngeal carcinoma cells to cisplatin-induced cytotoxicity. Voon YL; Ahmad M; Wong PF; Husaini R; Ng WT; Leong CO; Lane DP; Khoo AS Oncol Rep; 2015 Oct; 34(4):1692-700. PubMed ID: 26252575 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]